Servier

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1954-01-01

Employees: 251

Market Cap: -

Website: https://servier.com.br

Clinical Trials

Phase III LEAP-012 study shows len + pembro + TACE significantly improved PFS in intermediate-stage HCC patients

LEAP-012 trial showed len + pembro + TACE significantly improved PFS vs placebo + TACE in intermediate-stage HCC patients. OS data were immature, with a trend toward improvement. Safety profiles were consistent with known effects of the treatments. OS will be reassessed in future analyses.

Related Clinical Trials:

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Home Terms & Conditions Privacy Policy